PMID- 28318138
OWN - NLM
STAT- MEDLINE
DCOM- 20170327
LR  - 20170327
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 89
IP  - S1
DP  - 2017 Mar
TI  - Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in 
      patients after implantation of multiple biodegradable polymer-coated 
      sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial.
PG  - 555-564
LID - 10.1002/ccd.26947 [doi]
AB  - OBJECTIVE: This study sought to compare the clinical outcomes of 6-month versus 
      12-month dual antiplatelet therapy (DAPT) in patients receiving multiple 
      biodegradable polymer-coated sirolimus-eluting stents (BP-SES) implants. 
      BACKGROUND: The clinical outcomes for patients who undergo multiple BP-SES 
      implantation with different DAPT durations are uncertain. METHODS: In the 
      I-LOVE-IT 2 trial, 907 patients treated with multiple BP-SES (total stent number 
      >/=2) were assigned to receive 6-month (n = 440) or 12-month (n = 467) DAPT. The 
      primary endpoint was 12-month target lesion failure (TLF), which is a composite 
      of cardiac death, target vessel myocardial infarction (MI) or clinically 
      indicated target lesion revascularization. The major secondary endpoints were 
      12-month net adverse clinical events, a composite of all causes of death, MI, 
      stroke, any revascularization and bleeding. RESULTS: The number of stents per 
      patient between the 6-month and 12-month DAPT group was similar (2.4 +/- 0.7 vs. 
      2.4 +/- 0.7, P = 0.47). The incidence of 12-month TLF was comparable in the 6-month 
      and 12-month DAPT groups (9.3% vs.7.5%, Log-rank P = 0.33). However, landmark 
      analysis showed that 12-month DAPT, compared to 6-month DAPT, was associated with 
      a significantly lower risk of TLF (4.8% vs. 2.4%, Log-rank P = 0.049) at a cost 
      of a slightly increased risk of all bleeding events (0.5% vs. 1.7%, Log-rank 
      P = 0.07) between 6 and 12 months. CONCLUSIONS: In patients treated with multiple 
      BP-SES, 6- and 12-month DAPT had similar impacts on 12-month clinical outcomes. 
      Additionally, 12-month DAPT might reduce TLF between 6 and 12 months at the cost 
      of a slightly increased risk of all bleeding events. (c) 2017 Wiley Periodicals, 
      Inc.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Qi, Jing
AU  - Qi J
AD  - The Department of Cardiology, General Hospital of Shenyang Military Region, 
      Shenyang, China.
AD  - The Department of Cardiology, The First Clinical College, Liaoning University of 
      Traditional Chinese Medicine, Shenyang, China.
FAU - Li, Yi
AU  - Li Y
AD  - The Department of Cardiology, General Hospital of Shenyang Military Region, 
      Shenyang, China.
FAU - Li, Jing
AU  - Li J
AD  - The Department of Cardiology, General Hospital of Shenyang Military Region, 
      Shenyang, China.
FAU - Jing, Quanmin
AU  - Jing Q
AD  - The Department of Cardiology, General Hospital of Shenyang Military Region, 
      Shenyang, China.
FAU - Xu, Kai
AU  - Xu K
AD  - The Department of Cardiology, General Hospital of Shenyang Military Region, 
      Shenyang, China.
FAU - Gao, Chuanyu
AU  - Gao C
AD  - The Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou, 
      China.
FAU - Ma, Likun
AU  - Ma L
AD  - The Department of Cardiology, Anhui Provincial Hospital, Hefei, China.
FAU - Zhang, Zhi
AU  - Zhang Z
AD  - The Department of Cardiology, Third Affiliated Hospital of Liaoning Medical 
      College, Jinzhou, China.
FAU - Xu, Bo
AU  - Xu B
AD  - Catheterization Laboratory, Fuwai Hospital, Chinese Academy of Medical Sciences, 
      Beijing, China.
FAU - Han, Yaling
AU  - Han Y
AD  - The Department of Cardiology, General Hospital of Shenyang Military Region, 
      Shenyang, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polymers)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - *Absorbable Implants
MH  - Acute Coronary Syndrome/diagnostic imaging/mortality/*therapy
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/adverse effects/*instrumentation/mortality
MH  - Cardiovascular Agents/*administration & dosage/adverse effects
MH  - China
MH  - Coronary Angiography
MH  - Coronary Artery Disease/diagnostic imaging/mortality/*therapy
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/etiology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Polymers
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sirolimus/*administration & dosage/adverse effects
MH  - Stroke/etiology
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - biodegradable polymer
OT  - dual antiplatelet therapy
OT  - multiple stent implantation
EDAT- 2017/03/21 06:00
MHDA- 2017/03/28 06:00
CRDT- 2017/03/21 06:00
PHST- 2016/12/15 00:00 [received]
PHST- 2017/01/04 00:00 [revised]
PHST- 2017/01/04 00:00 [accepted]
PHST- 2017/03/21 06:00 [entrez]
PHST- 2017/03/21 06:00 [pubmed]
PHST- 2017/03/28 06:00 [medline]
AID - 10.1002/ccd.26947 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2017 Mar;89(S1):555-564. doi: 10.1002/ccd.26947.